| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:11294987 | IVR | 3 mg/kg | - | No significant effects observed | - |
| IVR | 0.3 mg/kg | - | No significant effects observed | - | |
| IVR | 0.03 mg/kg | 0.03 mg/kg | Increased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 0.03 mg/kg | 0.03 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 0.03 mg/kg | 0.03 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| PMID:27240701 | IVR | 1 mL/kg/day | 1 mL/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVR | 1 mL/kg/day | 1 mL/kg/day | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mL/kg/day | 1 mL/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mL/kg/day | 1 mL/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mL/kg/day | 1 mL/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:7746793 | IVR | 45.3 - 90.5 mg/kg | 45.3 - 90.5 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 45.3 - 90.5 mg/kg | 45.3 - 90.5 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 45.3 - 90.5 mg/kg | 45.3 - 90.5 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 45.3 - 90.5 mg/kg | 45.3 - 90.5 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 45.3 - 90.5 mg/kg | 45.3 - 90.5 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:8521242 | IVR | 20 mg/kg/day | 20 mg/kg/day | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.